Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech
Carolin Barth Is New CEO
Executive Summary
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.
You may also be interested in...
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
New UK Biotech MiroBio Raises $34m For Autoimmune Disease Research
Company is keeping its cards close to chest on exact mechanism as it enters increasingly competitive autoimmune disease field.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.